PD L1 News and Research

RSS

Low-dose radiation therapy may increase uptake of therapeutic nanoparticles by brain tumors

A new study led by Massachusetts General Hospital (MGH) investigators finds that radiation therapy may increase the uptake of therapeutic nanoparticles by glioblastomas, raising the possibility of using both growth-factor-targeted and immune-system-based therapies against the deadly brain tumor.

28 Mar 2019

Radiolabeled protein lights up tumor to reveal where cancer drugs are working

Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.

28 Mar 2019

City of Hope exhibits current studies and data on cancer therapies at AACR

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.

22 Mar 2019

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.

21 Mar 2019

Preclinical data shows combination immunotherapy could suppress tumor growth in the liver

Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with liver cancer is on the rise.

14 Mar 2019

First molecular test predicts treatment response for kidney cancer

Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But immunotherapy is expensive, benefits only a subset of patients and is futile in the majority of patients.

19 Feb 2019

Combination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

18 Feb 2019

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

18 Feb 2019

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

15 Feb 2019

Novel approach uses small amounts of tissue to quantify PD-L1 expression levels in tumors

Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer.

14 Feb 2019

Immunotherapy may be better than chemotherapy for Merkel cell carcinoma

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

11 Feb 2019

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Squamous cell carcinoma is one of the most common cancers of the skin and mucosa. Treatment options for the advanced stage have been very limited for patients with tumors of the head and neck, i.e. in the mouth, the pharynx or the larynx: If recurrences or metastases occur during or after platinum-based chemotherapy, the disease is generally considered incurable.

18 Jan 2019

New potential immunotherapy target in pancreatic cancer identified

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.

11 Jan 2019

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

International study increases group of lung cancer patients who may benefit from immunotherapy

The strategy for triggering the patient's own immune system to attack cancer, immunotherapy, is proving effective for more and more tumor types, although to varying degrees.

4 Dec 2018

Study reveals unknown mechanism that protects tumor cells from NK cell-mediated cytotoxicity

Cancer cells have evolved multiple escape strategies to circumvent the body's immune defenses such as the attack by Natural Killer (NK) cells which normally swiftly kill abnormal cells by releasing cytotoxic products.

24 Oct 2018

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

23 Oct 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

PD L1 News and Research

Low-dose radiation therapy may increase uptake of therapeutic nanoparticles by brain tumors

Radiolabeled protein lights up tumor to reveal where cancer drugs are working

City of Hope exhibits current studies and data on cancer therapies at AACR

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

Preclinical data shows combination immunotherapy could suppress tumor growth in the liver

First molecular test predicts treatment response for kidney cancer

Combination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Drug combinations could become first-line treatment for metastatic kidney cancer

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Novel approach uses small amounts of tissue to quantify PD-L1 expression levels in tumors

Immunotherapy may be better than chemotherapy for Merkel cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

New potential immunotherapy target in pancreatic cancer identified

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

International study increases group of lung cancer patients who may benefit from immunotherapy

Study reveals unknown mechanism that protects tumor cells from NK cell-mediated cytotoxicity

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News